Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.62 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382394 | 0.98 | NR1H4 (0.60) | NR1H4GABRA1GABRA2PTGS2ENPP2 | |
| SCHEMBL1712215 | 0.98 | NR1H4 (0.60) | NR1H4GABRA1GABRA2PTGS2ENPP2 | |
| SCHEMBL1712723 | 0.82 | NR1H4 (0.53) | NR1H4GABRA1GABRA2PTGS2ENPP2 | |
| SCHEMBL2382233 | 0.81 | NR1H4 (0.65) | NR1H4GABRA1GABRA2PTGS2ENPP2 | |
| SCHEMBL2381928 | 0.81 | NR1H4 (0.59) | NR1H4GABRA1GABRA2PTGS2ENPP2 | |
| SCHEMBL2381881 | 0.80 | NR1H4 (0.65) | NR1H4ENPP2CNR1CNR2 | |
| SCHEMBL12336804 | 0.80 | NR1H4 (0.53) | NR1H4GABRA1GABRA2PTGS2ENPP2 | |
| SCHEMBL1712427 | 0.79 | NR1H4 (0.62) | NR1H4GABRA1GABRA2PTGS2CNR1 | |
| SCHEMBL2381422 | 0.79 | NR1H4 (0.57) | NR1H4GABRA1GABRA2PTGS2ENPP2 | |
| SCHEMBL2383338 | 0.79 | NR1H4 (0.54) | NR1H4GABRA1GABRA2PTGS2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550254-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| US-8252826-B2 | Cyclopentyl- and cycloheptylpyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | US | disclosed |
| WO-2011117163-A1 | CYCLOPENTYL - AND CYCLOHEPTYLPYRAZOLES AS FXR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237628-A1 | CYCLOPENTYL- AND CYCLOHEPTYLPYRAZOLES | CYP1B1, CYP1A1, CYP4F3 | NR1H4 644/4885GABRA1 366/4885GABRA2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.